Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
Category: prescription drugs
Clinicians Who Learn Of A Patient’s Opioid Death Modestly Cut Back On Prescriptions
A study published Thursday shows that doctors, dentists and other medical providers cut overall opioid dosages by nearly 10 percent after receiving notification of a death from a medical examiner and information on safe prescribing.
Clinicians Who Learn Of A Patient’s Opioid Death Modestly Cut Back On Prescriptions
A study published Thursday shows that doctors, dentists and other medical providers cut overall opioid dosages by nearly 10 percent after receiving notification of a death from a medical examiner and information on safe prescribing.
Pharmacy-Made Pain Creams Flagged On Fears Of Medicare Fraud And Risk
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
Pharmacy-Made Pain Creams Flagged On Fears Of Medicare Fraud And Risk
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
Medicaid Expansion Making Diabetes Meds More Accessible To Poor, Study Shows
The number of diabetes drug prescriptions filled for low-income people enrolled in Medicaid rose sharply in states that expanded eligibility for the program under the Affordable Care Act, according to a new study.
How Rival Opioid Makers Sought To Cash In On Alarm Over OxyContin’s Dangers
Fentanyl and other painkillers marketed as safer than Purdue Pharma’s blockbuster drug left their own trail of overdose deaths.
Patients With Chronic Pain Feel Caught In An Opioid-Prescribing Debate
States are passing laws that limit a doctor’s ability to prescribe opioids. Doctors and patients alike are wrestling with what that means in cases of chronic pain.
To Tame Prescription Prices, HHS Dips A Toe Into Drug Importation Stream
The Trump administration signals it is willing to consider such a move if it is carefully tailored to focus solely on specific situations where a high-priced drug is made by one company.
Purdue Pharma Edits Public Service Ad In Washington Post
Did OxyContin maker admit opioids can be dangerous even when patients take them as prescribed — then walk it back?
